Clinical Outcomes of Sanshen Fuzheng Decoction in Preventing Chemotherapy-induced Neutropenia in Ovarian Cancer

This study aimed to explore the clinical value of Sanshen Fuzheng Decoction in the secondary prevention of chemotherapy-induced neutropenia in patients with malignant ovarian tumors. Sixty patients with primary ovarian cancer who received postoperative chemotherapy between January 2022 and January 2023 were enrolled. Using a random number table, they were equally divided into a treatment group and a control group (n = 30 each). The control group received standard paclitaxel plus carboplatin (TP) chemotherapy (paclitaxel + carboplatin), while the treatment group received TP combined with Sanshen Fuzheng Decoction. Baseline indicators were not significantly different between groups before chemotherapy (P > 0.05). On days 3, 7, 10, 14, and 20 post chemotherapy, both groups showed increased hemoglobin (Hb), red blood cell (RBC), neutrophil (NE) counts, interleukin-2 (IL-2), and interleukin-6 (IL-6), and decreased white blood cell (WBC), lymphocyte (LYM), and platelet (PLT) counts. Compared to the control group, the treatment group showed significantly greater increases in Hb, RBC, NE, interleukin-2 (IL-2), and interleukin-6 (IL-6), and the decrease in LYM was more obvious, while the decrease in WBC and PLT was smaller (all P < 0.05). The total dose of recombinant human granulocyte colony-stimulating factor (rhG-CSF) and the duration of leukopenia were significantly lower in the treatment group (P < 0.05). Additionally, more improvement in Traditional Chinese Medicine (TCM) symptom scores (fatigue, weakness, sweating, dizziness, pale complexion) was observed in the treatment group. The incidence of chemotherapy-related toxic side effects was significantly lower in the treatment group (P < 0.05). No significant differences were observed in liver/kidney function, febrile neutropenia, or absolute neutrophil count (ANC) reduction (P > 0.05). San shen Fu zheng Decoction, as an adjunct to chemotherapy in ovarian cancer, showed potential benefits in improving hematological recovery, reducing rhG-CSF use, and alleviating treatment-related symptoms.